Plasma lipids are altered in Gaucher disease: Biochemical markers to evaluate therapeutic intervention

Blood Cells, Molecules, and Diseases

Volumn 40, Issue 3, 2008, Pages 420-427

  Meikle, Peter J ^a,b   Whitfield, Philip D ^c   Rozaklis, Tina ^a   Blacklock, David ^a   Duplock, Stephen ^a   Elstein, Deborah ^d   Zimran, Ari ^d   Mengel, Eugen ^e   Cannell, Paul ^f   Hopwood, John J ^a,b   Fuller, Maria ^a,b  

^a Lysosomal Diseases Research Unit   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Gaucher disease; Genetic disorders; Lipids; Mass spectrometry; Therapy

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; CERAMIDE DERIVATIVE; CERAMIDE DIHEXOSIDE; CHITOTRIOSIDASE; GANGLIOSIDE GM3; GLUCOSYLCERAMIDE; LIPID; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPID; SPHINGOLIPID; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; GAUCHER DISEASE; HEXOSAMINIDASES; HUMANS; LIPIDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 41949140818     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.10.004     Document Type: Article

References (24)

1. Brady R.O., Kanfer J.N., Bradley R.M., et al. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45 (1966) 1112-1115
2. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York 3635-3668
3. Zimran A., Sorge J., Gross E., et al. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 2 (1989) 349-352
4. Pastores G.M., Weinreb N.J., Aerts H., et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 41 (2004) 4-14
5. Gelb M.H., Turecek F., Scott C.R., et al. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J. Inherit. Metab. Dis. 29 (2006) 397-404
6. Meikle P.J., Grasby D.J., Dean C.J., et al. Newborn screening for lysosomal storage disorders. Mol. Genet. Metab. 88 (2006) 307-314
7. Hollak C.E., van Weely S., van Oers M.H., et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93 (1994) 1288-1292
8. Boot R.G., Verhoek M., de Fost M., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103 (2004) 33-39
9. Gornati R., Berra B., Montorfano G., et al. Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease. J. Inherit. Metab. Dis. 25 (2002) 47-55
10. Trajkovic-Bodennec S., Bodennec J., and Futerman A.H. Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes. Blood Cells Mol. Diseases 33 (2004) 77-82
11. Bodennec J., Pelled D., Riebeling C., et al. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide. FASEB J. 16 (2002) 1814-1816
12. Kacher Y., and Futerman A.H. Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options. FEBS Lett. 580 (2006) 5510-5517
13. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226 (1957) 497-509
14. Langmann T., Klucken J., Reil M., et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun. 257 (1999) 29-33
15. Takahashi Y., and Smith J.D. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11358-11363
16. Nilsson O., Hakansson G., Dreborg S., et al. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin. Genet. 22 (1982) 274-279
17. Ullman M.D., and McCluer R.H. Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives. J. Lipid Res. 18 (1977) 371-378
18. Dawson G., and Oh J.Y. Blood glucosylceramide levels in Gaucher's disease and its distribution amongst lipoprotein fractions. Clin. Chim. Acta 75 (1977) 149-153
19. Strasberg P.M., Warren I., Skomorowski M.A., et al. HPLC analysis of neutral glycolipids: an aid in the diagnosis of lysosomal storage disease. Clin. Chim. Acta 132 (1983) 29-41
20. Ullman M.D., Pyeritz R.E., Moser H.W., et al. Application of "high-performance" liquid chromatography to the study of sphingolipidoses. Clin. Chem. 26 (1980) 1499-1503
21. Whitfield P.D., Nelson P., Sharp P.C., et al. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol. Genet. Metab. 75 (2002) 46-55
22. Henneberry A.L., Wright M.M., and McMaster C.R. The major sites of cellular phospholipid synthesis and molecular determinants of fatty acid and lipid head group specificity. Mol. Biol. Cell 13 (2002) 3148-3161
23. Hunt A.N., Clark G.T., Attard G.S., et al. Highly saturated endonuclear phosphatidylcholine is synthesized in situ and colocated with CDP-choline pathway enzymes. J. Biol. Chem. 276 (2001) 8492-8499
24. Kolter T., and Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu. Rev. Cell Dev. Biol. 21 (2005) 81-103